furosemide and rofecoxib

furosemide has been researched along with rofecoxib in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Endemann, D; Fischereder, M; Kammerl, MC; Kees, F; Krämer, BK; Lackner, KJ; Nüsing, RM; Schweda, F; Stubanus, M1
Höcherl, K; Kees, F; Krämer, BK; Kurtz, A1
Klaus, G; Kömhoff, M; Nazarowa, S; Reinalter, SC; Seyberth, HW1
Balal, M; Besen, A; Dogan, A; Gonlusen, G; Inal, T; Kibar, M; Kose, F; Paydas, S1

Trials

1 trial(s) available for furosemide and rofecoxib

ArticleYear
Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2.
    Clinical pharmacology and therapeutics, 2001, Volume: 70, Issue:5

    Topics: Adult; Aldosterone; Creatinine; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diet, Sodium-Restricted; Dinoprostone; Diuretics; Furosemide; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Renin; Sodium; Sulfones

2001

Other Studies

8 other study(ies) available for furosemide and rofecoxib

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression.
    Kidney international, 2004, Volume: 65, Issue:6

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Calcineurin Inhibitors; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cyclosporine; Dinoprostone; Diuresis; Diuretics; Drug Interactions; Furosemide; Isoenzymes; Kidney; Lactones; Loop of Henle; Male; Membrane Proteins; Natriuresis; Potassium; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Sulfones

2004
Increased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:7

    Topics: Adolescent; Adult; Blood Pressure; Child; Child, Preschool; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Furosemide; Humans; Indomethacin; Lactones; Male; Retrospective Studies; Sex Factors; Sulfones; Systole; Time Factors

2006
Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with furosemide on renal functions and renal Cox-2 expression in rats.
    Clinical and experimental nephrology, 2010, Volume: 14, Issue:1

    Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Furosemide; Gene Expression; Kidney; Lactones; Male; Osmolar Concentration; Potassium; Rats; Rats, Wistar; Renin; Sulfones; Urine

2010